In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Getting Wired for a World of Individuals

Executive Summary

Four converging forces--consumer activism, advances in information management, improved medical technology, and scientific progress--will transform health care and put individual patient-consumers at the heart of the process. Any pharmaceutical company that wants to serve this new market will need to collect personal data from millions of people, and use the information it already owns more effectively, in order to produce better and more economical drugs.Building an electronic infrastructure that will enable a pharmaceutical company to do these things is a major challenge because of the variety of sources, multiplicity of formats, and complexity of the data Pharma must handle. But the emerging e-business technologies--including the Internet, new data warehousing tools, and increasingly sophisticated management systems--will provide a solution to many of these problems. And some industry leaders are already exploring their potential.

You may also be interested in...



When the Consumer Drives Demand

Empowered consumers are playing a more proactive role in almost all treatment decisions. For consumer-driven and lifestyle drugs, a fast-growing portion of pharma's portfolio, marketers still focus on physician detailing but must resist the temptation to rely only on physicians to interpret consumers' needs. Consumers have their own approach to evaluating the risks and rewards of a lifestyle-oriented drug. The fact that it outperforms placebo in clinical trials matters little: they expect it to be significantly better, and without unpleasant side effects. Companies must weigh these expectations early in the development process. Adjusting the paradigm where the physician is king is a major challenge. The perception that traditional detailing efforts generate the dollars, while consumer marketing only spends them, remains hard to change.

Execs On The Move: BioVentrix Shuffles Board

Avalon Healthcare appoints two new directors; Lantheus Holdings appoints new chief accounting officer; and more.

UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel